Thurfjell Lennart, Lilja Johan, Lundqvist Roger, Buckley Chris, Smith Adrian, Vandenberghe Rik, Sherwin Paul
GE Healthcare, Uppsala, Sweden Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
GE Healthcare, Uppsala, Sweden.
J Nucl Med. 2014 Oct;55(10):1623-8. doi: 10.2967/jnumed.114.142109. Epub 2014 Aug 21.
Clinical trials of the PET amyloid imaging agent (18)F-flutemetamol have used visual assessment to classify PET scans as negative or positive for brain amyloid. However, quantification provides additional information about regional and global tracer uptake and may have utility for image assessment over time and across different centers. Using postmortem brain neuritic plaque density data as a truth standard to derive a standardized uptake value ratio (SUVR) threshold, we assessed a fully automated quantification method comparing visual and quantitative scan categorizations. We also compared the histopathology-derived SUVR threshold with one derived from healthy controls.
Data from 345 consenting subjects enrolled in 8 prior clinical trials of (18)F-flutemetamol injection were used. We grouped subjects into 3 cohorts: an autopsy cohort (n = 68) comprising terminally ill patients with postmortem confirmation of brain amyloid status; a test cohort (n = 172) comprising 33 patients with clinically probable Alzheimer disease, 80 patients with mild cognitive impairment, and 59 healthy volunteers; and a healthy cohort of 105 volunteers, used to define a reference range for SUVR. Visual image categorizations for comparison were from a previous study. A fully automated PET-only quantification method was used to compute regional neocortical SUVRs that were combined into a single composite SUVR. An SUVR threshold for classifying scans as positive or negative was derived by ranking the PET scans from the autopsy cohort based on their composite SUVR and comparing data with the standard of truth based on postmortem brain amyloid status for subjects in the autopsy cohort. The derived threshold was used to categorize the 172 scans in the test cohort as negative or positive, and results were compared with categorization using visual assessment. Different reference and composite region definitions were assessed. Threshold levels were also compared with corresponding thresholds derived from the healthy group.
Automated quantification (using pons as the reference region) demonstrated 91% sensitivity and 88% specificity and gave 3 false-positive and 4 false-negative scans. All 3 false-positive cases were either borderline-normal by standard of truth or had moderate to heavy cortical diffuse plaque burden. In the test cohort, the concordance between quantitative and visual read categorization ranged from 97.1% to 99.4% depending on the selection of reference and composite regions. The threshold derived from the healthy group was close to the histopathology-derived threshold.
Categorization of (18)F-flutemetamol amyloid imaging data using an automated PET-only quantification method showed good agreement with histopathologic classification of neuritic plaque density and a strong concordance with visual read results.
正电子发射断层扫描(PET)淀粉样蛋白成像剂(18)F-氟代甲磺酸美他莫尔的临床试验使用视觉评估将PET扫描分类为脑淀粉样蛋白阴性或阳性。然而,定量分析可提供有关区域和整体示踪剂摄取的额外信息,并且可能对随时间推移以及跨不同中心的图像评估有用。我们以死后大脑神经炎性斑块密度数据作为真值标准来推导标准化摄取值比率(SUVR)阈值,评估了一种全自动定量分析方法,并比较了视觉和定量扫描分类。我们还将组织病理学得出的SUVR阈值与从健康对照得出的阈值进行了比较。
使用了来自参与先前8项(18)F-氟代甲磺酸美他莫尔注射临床试验的345名受试者的同意数据。我们将受试者分为3组:尸检组(n = 68),包括临终时经尸检确认脑淀粉样蛋白状态的患者;测试组(n = 172),包括33例临床可能患有阿尔茨海默病的患者、80例轻度认知障碍患者和59名健康志愿者;以及105名志愿者的健康组,用于定义SUVR的参考范围。用于比较的视觉图像分类来自先前的一项研究。使用一种仅PET的全自动定量分析方法来计算区域新皮质SUVR,将其合并为单个复合SUVR。通过根据尸检组PET扫描的复合SUVR对其进行排序,并将数据与基于尸检组受试者死后脑淀粉样蛋白状态的真值标准进行比较,得出用于将扫描分类为阳性或阴性的SUVR阈值。得出的阈值用于将测试组中的172次扫描分类为阴性或阳性,并将结果与使用视觉评估的分类进行比较。评估了不同的参考和复合区域定义。还将阈值水平与从健康组得出的相应阈值进行了比较。
自动定量分析(使用脑桥作为参考区域)显示敏感性为91%,特异性为88%,有3次假阳性扫描和4次假阴性扫描。所有3例假阳性病例按真值标准要么接近正常,要么有中度至重度皮质弥漫性斑块负担。在测试组中,根据参考和复合区域的选择,定量和视觉读数分类之间的一致性范围为97.1%至99.4%。从健康组得出的阈值接近组织病理学得出的阈值。
使用仅PET的自动定量分析方法对(18)F-氟代甲磺酸美他莫尔淀粉样蛋白成像数据进行分类,与神经炎性斑块密度的组织病理学分类显示出良好的一致性,并且与视觉读数结果有很强的一致性。